Access to high-quality cancer gene mutation profiling has evolved significantly since 2010, however, personalized cancer therapy remains a big data problem. For example, the number of unique single, double, and triple drug combinations from just 150 cancer drugs would be in excess of 540,000. This is simply too many potential therapies for any physician or group of physicians to evaluate.
ROSALIND addresses this problem, turning big data into actionable data. Designed to empower physicians to make better personalized cancer treatment decisions, ROSALIND is a dynamic, programmable computer simulation of how cell signaling pathways are altered by specific gene mutations that are associated with specific types of cancers. The underlying patent pending technology produces a comprehensive mathematical model of cell signaling and is intended to help physicians identify optimal personalized cancer treatment options.
The current version of ROSALIND is an advanced system that has successfully undergone initial validation and is capable of representing more than 4.5 million cell signaling relationships. This model continues to grow as new peer reviewed data becomes available.
If you are a physician and would like to order a ROSALIND evaluation for one of your patients, please visit the oncologists page of the ROSALIND website at http://www.rosalindonline.com/for-oncologists.html.